Bill Anderson worked at Dow Pharmaceutical Sciences, Inc. (a wholly-owned subsidiary of Valeant Pharmaceuticals International since December 31, 2008) from 2003 until he retired in June 2010. He had most recently served as Managing Director and previously served as Chief Financial Officer and Vice President, Finance and Administration.
Earlier in his career, Mr. Anderson held similar executive-level positions at other biopharmaceutical companies including Syntex, Chiron, Glycomed, Fusion Medical Technologies and BioMarin Pharmaceutical. Mr. Anderson also served as an officer in the US Army Corps of Engineers as a strategic planner, profit and loss operation manager at General Electric and as a finance manager at Memorex. Mr. Anderson earned a B.S. in Engineering from the United States Military Academy at West Point, an M.S. in Administration from George Washington University, Washington, D.C., and an M.B.A. from Harvard University, Cambridge, Massachusetts.
Suzanne L. Bruhn, Ph.D. is Senior Vice President, Strategic Planning and Program Management for Shire Human Genetic Therapies (HGT), a division of Shire (NASDAQ: SHPGY) (LSE: SHP) specializing in the development and commercialization of treatments for orphan diseases. Since starting at Shire HGT in 1998, Dr. Bruhn has been responsible for establishing the program management function, driving strategic planning and portfolio management, and for Global Regulatory Affairs. Dr. Bruhn has played a key role in the development, registration, and global expansion of market-leading REPLAGAL® and of ELAPRASE®, as well as Shire HGT's portfolio expansion through acquisitions. Prior to Shire HGT, Dr. Bruhn held various positions at Cytotherapeutics, Inc. Dr. Bruhn holds a Ph.D. in Chemistry from MIT and was a Postdoctoral Fellow in the Department of Human Genetics at Harvard Medical School.
Richard L. Franklin, M.D., Ph.D., holds positions on many Boards of Directors, including Chairman of the Board at both SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of medical devices, DMS Data Systems, an Internet-based information services company, Chief Executive Officer and Director of Tarix Pharmaceuticals, a drug development company, and Chairman of Pathfinder, LLC, a regenerative medicine company. From 1996 to 2002, Dr. Franklin served as Chief Executive and Director of Phairson, Ltd., a medical product development company and worked as a consultant for healthcare industry firms.
Dr. Franklin founded Richard Franklin & Associates, worked with Boston Capital Group and was the head of Healthcare Corporate Finance at Tucker Anthony, an investment banking firm. Dr. Franklin received a B.A. in economics from Harvard University, an M.A. in mathematics from the University of Wisconsin, a Ph.D. in mathematics from Brandeis University and an M.D. from Boston University School of Medicine.
Dr. Keltner has served as a director of Raptor Pharmaceutical Corp. since September 2009. Since May 2011, Dr. Keltner has been the chief executive officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy. Dr. Keltner was been the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. He is also Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.
Dr. Keltner holds positions on the boards of Infostat, Oregon Life Sciences, and Goodwell Technologies. He is a previous director on the boards of Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation. He has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma. He is currently a member of the American Society of Clinical Oncology, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored several research publications. We nominated Dr. Keltner to the board of directors due to his practical experience as a current chief executive officer of a life sciences company and due to his medical knowledge and network within the biotechnology industry.
Erich Sager is a founding partner of Limetree Capital SA, a Swiss-based investment banking boutique. Mr. Sager also serves as Chairman and member of the Board of Directors at Calltrade Carrier Services AG, a European wholesale phone operator, since 2004. He is also a current Board member of Zecotek Medical Systems Inc. and Pulse Capital Corp.
Mr. Sager served for several years on the Board of Directors of BioMarin Pharmaceutical Inc. and as Chairman of LaMont Asset Management SA, a private investment management firm. Mr. Sager has held the position of Senior Vice President, Head of the Private Banking for Dresdner Bank (Switzerland) Ltd, Vice President, Private Banking, Head of the German Desk for Deutsche Bank (Switzerland) Ltd., and various positions at banks in Switzerland. Mr. Sager received a business degree from the School of Economics and Business Administration, Zurich, Switzerland.
Vijay B. Samant is President and Chief Executive Officer of Vical Inc., a major player in the development of DNA vaccines for infectious diseases and cancer therapeutics. Prior to Vical, Mr. Samant spent more than 20 years in diverse U.S and international sales, marketing, operations, and business development experience with Merck, including positions as Vice President of Vaccine Operations in the Manufacturing Division, Vice President of Business Affairs, and Executive Director of Materials Management. Mr. Samant has also been: a member of the Board of Trustees for the International Vaccine Institute (IVI, Seoul, Korea) since 2008; a member of the Board of Trustees for the National Foundation for Infectious Diseases (NFID, Bethesda, MD) since 2003; and a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010. Mr. Samant holds an M.B.A from the Sloan School of Management at the Massachusetts Institute of Technology, as well as an M.S. in Chemical Engineering from Columbia University, and a B.S. in Chemical Engineering from the University of Bombay.
Christopher M. Starr, Ph.D., co-founded Raptor in 2005 and serves as our Chief Executive Officer and member of our Board of Directors. In 1997, Dr. Starr co-founded BioMarin Pharmaceutical Inc., serving as Senior Vice President and Chief Scientific Officer, where he led a scientific operations team to successfully develop commercial manufacturing processes for enzyme replacement products, and supervised the cGMP design, construction and licensing of a manufacturing facility. From 1991 to 1998, at BioMarin's predecessor company, Glyko, Inc., Dr. Starr supervised and directed research, development and commercial programs as Vice President of Research and Development.
Dr. Starr studied nuclear membrane transport, cell surface receptor function, and protein intracellular trafficking as a National Research Council Associate at the National Institutes of Health (NIH). Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York, Health Science Center, Syracuse.
Timothy P. Walbert is Chairman, President and Chief Executive Officer of Horizon Pharma, Inc, a privately held biopharmaceutical company focused on developing and commercializing innovative medicines in arthritis, pain and inflammatory diseases. Prior to Horizon Pharma, Mr. Walbert was President, Chief Executive Officer and Director of IDM Pharma, Inc., a publicly traded oncology-focused biotechnology company. For more than 20 years, Mr. Walbert held executive positions in general management, corporate strategy, sales, U.S. and international marketing and commercial operations at such biopharmaceutical industry leaders as Abbott, G.D. Searle/Pharmacia, NeoPharm, Merck and Wyeth. At. Abbott, Mr. Walbert served as divisional vice president and general manager, immunology at Abbott, leading the global launch of HUMIRA, which attained over six billion in 2010 sales. Mr. Walbert serves on the Board of Directors of XOMA Ltd., the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO) and the Greater Chicago Arthritis Foundation. Mr. Walbert holds a B.A. in Business and Marketing from Muhlenberg College.